Arena files lorcaserin hydrochloride MAA with Swissmedic Arena Pharmaceuticals, Inc. announced today the filing with the Swiss wellness authority, Swissmedic, of a Marketing Authorization Program for lorcaserin hydrochloride, an investigational drug applicant in Switzerland. The meant indication is as an adjunct to exercise and diet for excess weight control in sufferers with a short body mass index of 30 kg/m or better , or 27 kg/m or better in the presence of at least one pounds related comorbid condition click here . Arena expects that Swissmedic encourage the filing afterwards this month and confirm the filing is definitely sufficiently complete allowing a substantive review procedure.
The average scores of all patients on scales utilized to measure the intensity of strokes improved after treatment. Argatroban and additional similar agents have not been shown to be effective by themselves, but these promising early results with mixture therapy warrant further research, the authors write. ‘Low-dose agratroban combined with intravenous rtPA may be safe and could produce faster and more complete recanalization than will rtPA only,’ they conclude. A second stage of the trial, in which 50 more patients will be enrolled, is now under way. ‘The equilibrium stage in the evaluation of the risk-benefit stability of the combined therapy can ultimately be established only within an adequately powered, blinded scientific trial with a proper interim monitoring for early advantage and harm,’ they write..